PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes

Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial

(2016) Maria Sessa et al.   LANCET

Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation

(2015) J. D. Scandling et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy

(2015) Francesca D’Addio et al.   Cell Stem Cell

Factors impeding the discovery of an intervention-based treatment for type 1 diabetes

(2015) M. G. von Herrath et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice

(2015) Ronald G. Gill et al.   DIABETES

Current Concepts on the Pathogenesis of Type 1 Diabetes—Considerations for Attempts to Prevent and Reverse the Disease

(2015) Mark A. Atkinson et al.   DIABETES CARE

The rise, fall, and resurgence of immunotherapy in type 1 diabetes

(2015) Moufida Ben Nasr et al.   PHARMACOLOGICAL RESEARCH

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis

(2014) F. D'Addio et al.   DIABETES

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

(2013) Stephen E Gitelman et al.   Lancet Diabetes & Endocrinology

Human Islets Express a Marked Proinflammatory Molecular Signature Prior to Transplantation

(2012) Mark J. Cowley et al.   CELL TRANSPLANTATION

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immunological Applications of Stem Cells in Type 1 Diabetes

(2011) Paolo Fiorina et al.   ENDOCRINE REVIEWS

The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo

(2011) J. Yang et al.   JOURNAL OF IMMUNOLOGY

A Novel Clinically Relevant Strategy to Abrogate Autoimmunity and Regulate Alloimmunity in NOD Mice

(2010) A. Vergani et al.   DIABETES

Targeting the CXCR4-CXCL12 Axis Mobilizes Autologous Hematopoietic Stem Cells and Prolongs Islet Allograft Survival via Programmed Death Ligand 1

(2010) P. Fiorina et al.   JOURNAL OF IMMUNOLOGY

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes

(2009) M. J. Haller et al.   DIABETES CARE

C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus

(2009) Carlos E. B. Couri   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes

(2009) P. Fiorina et al.   JOURNAL OF IMMUNOLOGY

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes

(2008) P. Fiorina et al.   DIABETES